Article
Preventing large deletions and chromosome loss in engineered human primary T cells by CasPlus with optimized guide RNAs
2025-01-31
Abstract excerpt
Genetically engineered T-cell therapies rely heavily on genome editing tools, such as the CRISPR/Cas9 system. However, unintended on-target chromosomal alterations, including large deletions and chromosome loss can occur and pose significant risks including tumorigenesis. Here we combined CasPlus and optimized guide RNAs to reduce these issues in CRISPR/Cas9 engineering human primary T cells. CasPlus, which integr...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- babc33c8-5685-5184-bd13-42fe0434f1f6
- DOI
- 10.1101/2025.01.29.635575
